November 10, 2020 -- CollPlant, a regenerative medicine company, is developing an antiviral agent for the potential treatment of COVID-19 patients. Early in vitro results suggest that CollPlant's formulation inhibits avian coronavirus infectivity.
The agent is based on the company's proprietary recombinant human type I collagen (rhCollagen) embedded with silver nanoparticles (AgNP). CollPlant produces the product on its plant-based genetic engineering technology.
The antiviral treatment is being evaluated in vitro using avian coronavirus grown on epithelial cells as a model of human coronavirus SARS-CoV-2. Efficacy of the treatment was assessed for the ability to protect epithelial cells from lethal doses of the virus. The results found a significant reduction in infectivity of the model with the rhCollagen-AgNP complexes.
Copyright © 2020 scienceboard.net